Enovid (nitric oxide nasal spray) / SaNOtize - LARVOL DELTA

Antifungal efficacy of a novel nitric oxide releasing solution in the presence of keratin. (PubMed, Front Cell Infect Microbiol) - "This study evaluated the antifungal activity of a nitric oxide-releasing solution (NORS) against clinical isolates of Trichophyton mentagrophytes, Trichophyton tonsurans, and Epidermophyton floccosum, comparing MIC and MFC profiles to efinaconazole and assessing keratin associated inhibition relative to terbinafine. Unlike terbinafine, whose efficacy decreased significantly in keratin-rich environments, NORS retained antifungal activity in the presence of human nail keratin. These results support further clinical evaluation of NO-based antifungals as potential treatments for onychomycosis and tinea pedis."

Journal • Dermatology • Infectious Disease

NONS-RARS-01: Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis (clinicaltrials.gov) - P2 | N=162 | Completed | Sponsor: Sanotize Research and Development corp. | Active, not recruiting ➔ Completed | Trial completion date: Feb 2025 ➔ Nov 2025

Trial completion • Trial completion date • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Novel Nitric Oxide-Releasing Formulations Show Fungicidal Potential for Superficial Dermatophyte Infection. (PubMed, J Fungi (Basel)) - "The clinical NORS treatment reduced the clinical symptom severity score by 67% on average, with no significant safety findings. These findings, in addition to existing publications, support NO-releasing formulations as potential therapies that warrant further clinical investigation for superficial fungal infection."

Journal • Dermatology • Infectious Disease

Broad-Spectrum Virucidal Activity of Nitric Oxide Nasal Spray (NONS) Against SARS-CoV-2 Variants and Major Respiratory Viruses. (PubMed, Viruses) - "Influenza A and B viruses showed the fastest loss of infectivity, reaching detection limits within 10-15 s. RSV, hMPV, HPIV-3, and human rhinovirus 14 were similarly inactivated within 1-2 min. These findings demonstrate that the NONS exhibits rapid and broad-spectrum virucidal activity against diverse respiratory viruses and supports its potential role in pandemic preparedness but also seasonal use."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Efficacy and safety of a topical nitric oxide-releasing solution (NORS) as a noninvasive treatment for plantar warts (verrucae plantaris). (PubMed, J Dermatolog Treat) - P2 | "NORS demonstrated favorable safety and early clinical activity, warranting larger, longer-term efficacy trials. ClinicalTrials.gov Identifier NCT05877313."

Clinical • Journal • Dermatology • Immunology • Oncology • Pain

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection (clinicaltrials.gov) - P3 | N=1389 | Terminated | Sponsor: Sanotize Research and Development corp. | Active, not recruiting ➔ Terminated; Recruitment challenges, i.e., not able to meet sample size targeted; secondary to the changing landscape of COVID-19 infection pathology.

Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

NONS-RARS-01: Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis (clinicaltrials.gov) - P2 | N=162 | Active, not recruiting | Sponsor: Sanotize Research and Development corp. | Trial primary completion date: Aug 2024 ➔ Feb 2025

Trial primary completion date • Otorhinolaryngology • Respiratory Diseases • Sinusitis

NONS-RARS-01: Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis (clinicaltrials.gov) - P2 | N=162 | Active, not recruiting | Sponsor: Sanotize Research and Development corp. | Recruiting ➔ Active, not recruiting

Enrollment closed • Otorhinolaryngology • Respiratory Diseases • Sinusitis

NONS-RARS-01: Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis (clinicaltrials.gov) - P2 | N=186 | Recruiting | Sponsor: Sanotize Research and Development corp. | Trial completion date: Sep 2024 ➔ Feb 2025

Trial completion date • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) (clinicaltrials.gov) - P2 | N=20 | Completed | Sponsor: Sanotize Research and Development corp. | Recruiting ➔ Completed | N=30 ➔ 20

Enrollment change • Trial completion • Dermatology • Oncology

NONS-RARS-01: Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis (clinicaltrials.gov) - P2 | N=186 | Recruiting | Sponsor: Sanotize Research and Development corp.

New P2 trial • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Sanotize Research and Development corp. | Phase classification: P2a ➔ P2 | Trial completion date: Dec 2023 ➔ Mar 2024

Phase classification • Trial completion date • Dermatology • Oncology

Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) (clinicaltrials.gov) - P2a | N=30 | Recruiting | Sponsor: Sanotize Research and Development corp. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Oncology

Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers (clinicaltrials.gov) - P1/2 | N=40 | Completed | Sponsor: Sanotize Research and Development corp. | Recruiting ➔ Completed

Trial completion

Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) (clinicaltrials.gov) - P2a | N=30 | Not yet recruiting | Sponsor: Sanotize Research and Development corp.

New P2a trial • Dermatology • Oncology

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection (clinicaltrials.gov) - P3 | N=1389 | Active, not recruiting | Sponsor: Sanotize Research and Development corp. | Trial completion date: Jul 2023 ➔ Apr 2024 | Trial primary completion date: Jul 2023 ➔ Jan 2024

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection (clinicaltrials.gov) - P3 | N=1389 | Active, not recruiting | Sponsor: Sanotize Research and Development corp. | Recruiting ➔ Active, not recruiting | N=13000 ➔ 1389 | Trial completion date: Nov 2022 ➔ Jul 2023 | Trial primary completion date: Nov 2022 ➔ Jul 2023

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Sanotize Research and Development corp. | Trial completion date: Dec 2022 ➔ Mar 2023 | Trial primary completion date: Dec 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date

"sanOtize nitric oxide nasal spray? (Enovid, Fabispray, VirX)" (,@MirthWormSlim)

SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomised trial. (PubMed, Lancet Reg Health Southeast Asia) - "Funding provided by Glenmark Pharmaceuticals Limited. Study medication provided by SaNOtize."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Sanotize Research and Development corp. | Trial completion date: May 2022 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection (clinicaltrials.gov) - P3 | N=13000 | Recruiting | Sponsor: Sanotize Research and Development corp. | Trial completion date: May 2022 ➔ Nov 2022 | Trial primary completion date: Mar 2022 ➔ Nov 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection (clinicaltrials.gov) - P3 | N=13000 | Recruiting | Sponsor: Sanotize Research and Development corp. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection (clinicaltrials.gov) - P3; N=13000; Not yet recruiting; Sponsor: Sanotize Research and Development corp.

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"Dr. Alvarez, why did inopulse fail for Covid, but @SanotizeD 's Enovid NO spray seems to work?" (,@DoodyGiuliani11)

Novel Coronavirus Disease